Replies to post #11406 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

OK, I didn't do the homework (that's our job but many of us
lay it off on you), but relied on your last mention here of
NN1731, which styled it "short-acting" vice "fast-acting":

>NVO has scrapped NovoSeven in favor of NN1731 (a short-acting FVIIa analogue)<
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=28922135

It's a good thing though that we get reminded that rapidity
of onset and duration of effect are completely separate
issues.

[Lewis R Goudy]

>NN1731 produced four– to 10-fold higher maximal thrombin generation rates<

That's the payload, and in the context of critical
care clearly a key datum.